Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
about
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyPLK1, A Potential Target for Cancer TherapyScreening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interferenceTherapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.TGF-β1 and TGF-β2 abundance in liver diseases of mice and menHuman ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1Cancer subclonal genetic architecture as a key to personalized medicine.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationCombined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.Selective targeting of tumor associated macrophages in different tumor models.Enhancing Gene-Knockdown Efficiency of Poly(-isopropylacrylamide) Nanogels
P2860
Q26991736-CD4F0FAD-867E-412D-AB9C-8479ACFC890BQ28078772-C0EE94A5-63E1-440A-9BED-1E3DF4459288Q28486133-064F011A-84C5-4DFB-9E47-2C2A508D1D17Q35828495-CE3211F9-EA76-4BB0-8CA6-794D8F0C3C5AQ37190089-BB85A73C-263A-49AF-A31E-1C5BC3342736Q37218015-CCE45538-9658-45E1-88B8-DDB99B4D9373Q37448116-4B577A94-2B58-4A25-8C0C-1B554F3552EDQ38989374-391F7997-735C-4743-B451-2A2520F82838Q39136346-A31F04B6-1A2F-4589-8C12-6EEE2DCA9AFBQ41480019-8D45DEC7-C569-4D38-95B0-9B8DE3A29438Q41879186-A8B6F3E4-BC8D-41AF-B5B6-9CA2424BBA3FQ49402953-877375D1-F75C-4B54-9B28-4EAB36E73E73Q49979720-8D5C9C10-83E0-4B7F-8B25-C8578D57C55CQ57359344-CF1466D1-B0C5-42E9-B364-68BE540861E1
P2860
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@ast
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@en
type
label
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@ast
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@en
prefLabel
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@ast
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@en
P2093
P2860
P50
P356
P1433
P1476
Reduced efficacy of the Plk1 i ...... low intratumoral drug levels.
@en
P2093
Alexander Benz
Bernd Kronenberger
Huedayi Korkusuz
Jörg Haupenthal
Knut Engels
Marta Canamero
Oliver Waidmann
Otto Kollmar
Susanne Kriener
Swantje Richter
P2860
P304
P356
10.1596/NEO.111366
P577
2012-05-01T00:00:00Z